Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Samala Swamy

Staten Island, NY Medical Doctor

NPI 1447227509 CMS profile 337806

1366 Victory Blvd, Suite B, Staten Island, NY 10301

Open in the dashboard

General payments

$2,706

126 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Samala Swamy of Staten Island, NY is reported in the CMS Open Payments database as having received $2,706 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $406 3
2021 General $617 24
2020 General $781 40
2019 General $902 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samala Swamy
  • New York median
  • Middle half of New York
  • National median

In program year 2025, general payments to Samala Swamy were reported at $0. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.

Show as a table
Year Samala Swamy New York median Middle half National median
2019 $902 $175 $53–$665 $163
2020 $781 $122 $37–$426 $114
2021 $617 $144 $44–$514 $132
2022 $406 $160 $51–$578 $149
2023 $0 $170 $54–$593 $160
2024 $0 $173 $56–$618 $164
2025 $0 $180 $58–$640 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Abbott Laboratories $711 8 payments
  2. Janssen Pharmaceuticals, Inc $403 28 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $336 13 payments
  4. AstraZeneca Pharmaceuticals LP $319 23 payments
  5. Novartis Pharmaceuticals Corporation $311 18 payments
  6. Amgen Inc. $211 12 payments
  7. iRhythm Technologies, Inc. $109 6 payments
  8. Sanofi-Aventis U.S. LLC $64 3 payments
  9. Pfizer Inc. $63 5 payments
  10. E.R. Squibb & Sons, L.L.C. $34 2 payments
  11. Other $146 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,695 124 payments
  2. Education $12 2 payments
Products named General payments · program years 2019–2022
  1. XARELTO $403 28 payments
  2. JARDIANCE $336 13 payments
  3. BRILINTA $319 23 payments
  4. ENTRESTO $311 18 payments
  5. DRAGONFLY OPSTAR $278 2 payments
  6. Repatha $211 12 payments
  7. Dragonfly OCT $164 2 payments
  8. Corlanor $139 8 payments
  9. PRESSUREWIRE $128 1 payment
  10. Xience Sierra Coronary Stent $121 2 payments
  11. Other $675 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record